Hologic, Inc. (NASDAQ:HOLX) insider Benjamin Jordan Cohn sold 3,437 shares of the business’s stock in a transaction that occurred on Wednesday, September 19th. The stock was sold at an average price of $41.50, for a total value of $142,635.50. Following the completion of the transaction, the insider now directly owns 16,520 shares in the company, valued at $685,580. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Shares of HOLX opened at $41.24 on Monday. The company has a market cap of $11.22 billion, a PE ratio of 20.32, a PEG ratio of 2.02 and a beta of 0.66. Hologic, Inc. has a 1 year low of $35.10 and a 1 year high of $45.09. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.99 and a current ratio of 1.29.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Tuesday, July 31st. The medical equipment provider reported $0.58 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.56 by $0.02. The business had revenue of $824.00 million for the quarter, compared to analysts’ expectations of $800.14 million. Hologic had a positive return on equity of 22.18% and a negative net margin of 2.47%. equities analysts forecast that Hologic, Inc. will post 2.24 EPS for the current fiscal year.

A number of research analysts recently commented on HOLX shares. TheStreet raised Hologic from a “c” rating to a “b” rating in a report on Tuesday, July 31st. BTIG Research reissued a “buy” rating and issued a $47.00 price target on shares of Hologic in a report on Thursday, August 2nd. Deutsche Bank boosted their price target on Hologic from $42.00 to $45.00 and gave the stock a “hold” rating in a report on Wednesday, August 1st. BidaskClub raised Hologic from a “sell” rating to a “hold” rating in a report on Friday, June 15th. Finally, Zacks Investment Research raised Hologic from a “sell” rating to a “hold” rating in a report on Thursday, August 2nd. Ten research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Hologic has an average rating of “Hold” and a consensus target price of $44.47.

Several institutional investors and hedge funds have recently modified their holdings of the company. Royal London Asset Management Ltd. purchased a new stake in shares of Hologic during the 2nd quarter worth approximately $4,837,000. WINTON GROUP Ltd purchased a new stake in shares of Hologic during the 2nd quarter worth approximately $5,837,000. Andra AP fonden purchased a new stake in shares of Hologic during the 2nd quarter worth approximately $3,581,000. Amussen Hunsaker Associates LLC purchased a new stake in shares of Hologic during the 2nd quarter worth approximately $159,000. Finally, Jane Street Group LLC raised its holdings in shares of Hologic by 595.7% during the 2nd quarter. Jane Street Group LLC now owns 48,029 shares of the medical equipment provider’s stock worth $1,909,000 after acquiring an additional 41,125 shares in the last quarter. 98.61% of the stock is currently owned by institutional investors and hedge funds.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Further Reading: What does relative strength index mean?

Insider Buying and Selling by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.